Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.72 |
| ▸ | MMP9 | P14780 | 8/20 | 0.72 |
| ▸ | MMP13 | P45452 | 7/20 | 0.72 |
| ▸ | MMP1 | P03956 | 6/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296107 | 1.00 | MMP2 (0.72) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6291766 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6296122 | 0.77 | MMP2 (0.86) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6292538 | 0.77 | MMP2 (0.73) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6292540 | 0.77 | MMP2 (0.73) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6291475 | 0.76 | MMP2 (0.77) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6291476 | 0.76 | MMP2 (0.77) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6296092 | 0.75 | MMP1 (1.00) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6291801 | 0.74 | MMP1 (0.81) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6292410 | 0.73 | MMP2 (1.00) | MMP2MMP9MMP13MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927216-B2 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-08-09 | — | — | US | claimed |
| EP-1322627-A1 | CYCLIC SULFONYL COMPOUNDS AS INHIBITORS OF METALLOPROTEASES | Bristol-Myers Squibb Pharma Company (US) | 2003-07-02 | — | — | EP | claimed |
| US-20020086853-A1 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-04 | — | — | US | claimed |
| WO-2002028846-A1 | CYCLIC SULFONYL COMPOUNDS AS INHIBITORS OF METALLOPROTEASES | DUPONT PHARMACEUTICALS COMPANY (US) | 2002-04-11 | — | — | WO | claimed |
| US-6927216-B2 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1322627-A1 | CYCLIC SULFONYL COMPOUNDS AS INHIBITORS OF METALLOPROTEASES | Bristol-Myers Squibb Pharma Company (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020086853-A1 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-04 | — | — | US | disclosed |
| WO-2002028846-A1 | CYCLIC SULFONYL COMPOUNDS AS INHIBITORS OF METALLOPROTEASES | DUPONT PHARMACEUTICALS COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086853-A1 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | DPP7, STS, CTRL | MMP2 11/4885MMP9 6/4885MMP13 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.